Literature DB >> 8876026

Lorazepam impairs perceptual integration of visual forms: a central effect.

A Giersch1, M Boucart, C Speeg-Schatz, F Muller-Kauffmann, J M Danion.   

Abstract

Previous studies have shown a lorazepam effect on visual perception. We tested whether this impairment resulted from a peripheral effect induced by benzodiazepines. A first experiment showed that a single dose of lorazepam induces an oculomotor imbalance without impairing visual acuity or accommodation. In a second experiment, we tested whether the impairment induced by lorazepam on visual perception still occurred in monocular vision. Subjects matched incomplete forms controlled on the spacing and alignment of their local contour elements. A reference object was first displayed and followed by two laterally displayed objects, a target and a distractor. The distractor was the mirror-reversed version of the target. Performance was impaired in the lorazepam group when the reference was an incomplete form with a spacing of 10.8' or 22.2' of arc. These results were not correlated with sedation. They confirm that lorazepam has a central deleterious effect on visual perception. A post-hoc analysis also suggested that lorazepam-treated subjects used asymmetry in the stimuli as a compensatory strategy. This result is discussed in relation to previous hypotheses about the physiological mechanisms that determine the effects of lorazepam on visual perception.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8876026     DOI: 10.1007/bf02246456

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  30 in total

Review 1.  Ophthalmologic effects of psychotropic medications.

Authors:  D A Malone; E G Camara; J H Krug
Journal:  Psychosomatics       Date:  1992       Impact factor: 2.386

2.  Global shape cannot be attended without object identification.

Authors:  M Boucart; G W Humphreys
Journal:  J Exp Psychol Hum Percept Perform       Date:  1992-08       Impact factor: 3.332

3.  Endstopping and curvature.

Authors:  A Dobbins; S W Zucker; M S Cynader
Journal:  Vision Res       Date:  1989       Impact factor: 1.886

4.  Line segregation.

Authors:  J Beck; A Rosenfeld; R Ivry
Journal:  Spat Vis       Date:  1989

5.  Component processes in the perception of bilaterally symmetric dot textures.

Authors:  B Jenkins
Journal:  Percept Psychophys       Date:  1983-11

6.  Parts of recognition.

Authors:  D D Hoffman; W A Richards
Journal:  Cognition       Date:  1984-12

7.  Detection of symmetry.

Authors:  F L Royer
Journal:  J Exp Psychol Hum Percept Perform       Date:  1981-12       Impact factor: 3.332

8.  Chronometric analysis of classification.

Authors:  M I Posner; R F Mitchell
Journal:  Psychol Rev       Date:  1967-09       Impact factor: 8.934

9.  Effects of lorazepam on perceptual integration of visual forms in healthy volunteers.

Authors:  A Giersch; M Boucart; J M Danion; P Vidailhet; F Legrand
Journal:  Psychopharmacology (Berl)       Date:  1995-05       Impact factor: 4.530

10.  Time course of the effects of diazepam and lorazepam on perceptual priming and explicit memory.

Authors:  F Legrand; P Vidailhet; J M Danion; D Grangé; A Giersch; M Van der Linden; J L Imbs
Journal:  Psychopharmacology (Berl)       Date:  1995-04       Impact factor: 4.530

View more
  3 in total

1.  Associations of selected medications and visual function: the Beaver Dam Eye Study.

Authors:  B E K Klein; R Klein; M D Knudtson; K E Lee; L G Danforth; J O Reinke; A M Adler
Journal:  Br J Ophthalmol       Date:  2003-04       Impact factor: 4.638

2.  Some facilitatory effects of lorazepam on dynamic visual binding.

Authors:  Mark A Elliott; Anne Giersch; Doerthe Seifert
Journal:  Psychopharmacology (Berl)       Date:  2005-12-23       Impact factor: 4.530

3.  Visual perception and its impairment in schizophrenia.

Authors:  Pamela D Butler; Steven M Silverstein; Steven C Dakin
Journal:  Biol Psychiatry       Date:  2008-07-01       Impact factor: 13.382

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.